vs
Side-by-side financial comparison of Journey Medical Corp (DERM) and FRANKLIN STREET PROPERTIES CORP (FSP). Click either name above to swap in a different company.
FRANKLIN STREET PROPERTIES CORP is the larger business by last-quarter revenue ($26.0M vs $16.1M, roughly 1.6× Journey Medical Corp). Journey Medical Corp runs the higher net margin — -7.8% vs -28.1%, a 20.4% gap on every dollar of revenue. On growth, Journey Medical Corp posted the faster year-over-year revenue change (27.3% vs -8.2%). Over the past eight quarters, Journey Medical Corp's revenue compounded faster (11.0% CAGR vs -8.7%).
Journey Medical Corp is a commercial-stage biopharmaceutical company specializing in dermatology treatments. It develops, manufactures and markets prescription and over-the-counter products addressing acne, atopic dermatitis, fungal skin infections and other dermal conditions, primarily serving healthcare providers and patients across the United States.
Franklin Street Properties Corp is a Massachusetts-based real estate investment trust (REIT) in the United States. It primarily invests in, owns, and operates high-quality office properties across major U.S. metropolitan markets, serving corporate tenants across various industry segments, and delivers stable long-term returns via rental income and strategic asset management.
DERM vs FSP — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $16.1M | $26.0M |
| Net Profit | $-1.2M | $-7.3M |
| Gross Margin | — | 59.4% |
| Operating Margin | -2.8% | -27.9% |
| Net Margin | -7.8% | -28.1% |
| Revenue YoY | 27.3% | -8.2% |
| Net Profit YoY | -182.0% | 14.1% |
| EPS (diluted) | $-0.04 | $-0.06 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $16.1M | $26.0M | ||
| Q3 25 | $17.0M | $27.3M | ||
| Q2 25 | $15.0M | $26.7M | ||
| Q1 25 | $13.1M | $27.1M | ||
| Q4 24 | $12.6M | $28.4M | ||
| Q3 24 | $14.6M | $29.7M | ||
| Q2 24 | $14.9M | $30.8M | ||
| Q1 24 | $13.0M | $31.2M |
| Q4 25 | $-1.2M | $-7.3M | ||
| Q3 25 | $-2.3M | $-8.3M | ||
| Q2 25 | $-3.8M | $-7.9M | ||
| Q1 25 | $-4.1M | $-21.4M | ||
| Q4 24 | $1.5M | $-8.5M | ||
| Q3 24 | $-2.4M | $-15.6M | ||
| Q2 24 | $-3.4M | $-21.0M | ||
| Q1 24 | $-10.4M | $-7.6M |
| Q4 25 | — | 59.4% | ||
| Q3 25 | — | 60.9% | ||
| Q2 25 | — | 59.9% | ||
| Q1 25 | — | 62.8% | ||
| Q4 24 | 82.3% | 59.7% | ||
| Q3 24 | 63.9% | 61.0% | ||
| Q2 24 | 56.0% | 64.2% | ||
| Q1 24 | 47.7% | 64.7% |
| Q4 25 | -2.8% | -27.9% | ||
| Q3 25 | -9.0% | -30.5% | ||
| Q2 25 | -19.2% | -29.2% | ||
| Q1 25 | -25.3% | -78.9% | ||
| Q4 24 | 17.7% | -29.9% | ||
| Q3 24 | -19.8% | -52.4% | ||
| Q2 24 | -19.7% | -68.0% | ||
| Q1 24 | -77.4% | -24.0% |
| Q4 25 | -7.8% | -28.1% | ||
| Q3 25 | -13.6% | -30.5% | ||
| Q2 25 | -25.3% | -29.5% | ||
| Q1 25 | -31.0% | -79.1% | ||
| Q4 24 | 12.1% | -30.0% | ||
| Q3 24 | -16.3% | -52.6% | ||
| Q2 24 | -22.6% | -68.2% | ||
| Q1 24 | -80.1% | -24.2% |
| Q4 25 | $-0.04 | $-0.06 | ||
| Q3 25 | $-0.09 | $-0.08 | ||
| Q2 25 | $-0.16 | $-0.08 | ||
| Q1 25 | $-0.18 | $-0.21 | ||
| Q4 24 | $0.10 | $-0.09 | ||
| Q3 24 | $-0.12 | $-0.15 | ||
| Q2 24 | $-0.17 | $-0.20 | ||
| Q1 24 | $-0.53 | $-0.07 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $24.1M | $30.6M |
| Total DebtLower is stronger | $25.3M | — |
| Stockholders' EquityBook value | $31.9M | $607.0M |
| Total Assets | $94.6M | $892.9M |
| Debt / EquityLower = less leverage | 0.79× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $24.1M | $30.6M | ||
| Q3 25 | $24.9M | $31.4M | ||
| Q2 25 | $20.3M | $29.4M | ||
| Q1 25 | $21.1M | $30.2M | ||
| Q4 24 | $20.3M | $41.1M | ||
| Q3 24 | $22.5M | $40.9M | ||
| Q2 24 | $23.9M | $30.2M | ||
| Q1 24 | $24.1M | $34.2M |
| Q4 25 | $25.3M | — | ||
| Q3 25 | $25.2M | — | ||
| Q2 25 | $25.1M | — | ||
| Q1 25 | $25.0M | — | ||
| Q4 24 | $24.9M | — | ||
| Q3 24 | $19.8M | — | ||
| Q2 24 | $19.7M | — | ||
| Q1 24 | $14.7M | — |
| Q4 25 | $31.9M | $607.0M | ||
| Q3 25 | $25.9M | $615.3M | ||
| Q2 25 | $19.2M | $624.7M | ||
| Q1 25 | $21.5M | $633.4M | ||
| Q4 24 | $20.1M | $655.9M | ||
| Q3 24 | $10.9M | $665.4M | ||
| Q2 24 | $11.3M | $682.1M | ||
| Q1 24 | $13.0M | $703.9M |
| Q4 25 | $94.6M | $892.9M | ||
| Q3 25 | $85.2M | $901.0M | ||
| Q2 25 | $81.2M | $903.2M | ||
| Q1 25 | $85.0M | $916.4M | ||
| Q4 24 | $80.2M | $946.9M | ||
| Q3 24 | $64.0M | $981.5M | ||
| Q2 24 | $65.2M | $1.0B | ||
| Q1 24 | $66.6M | $1.0B |
| Q4 25 | 0.79× | — | ||
| Q3 25 | 0.97× | — | ||
| Q2 25 | 1.30× | — | ||
| Q1 25 | 1.16× | — | ||
| Q4 24 | 1.24× | — | ||
| Q3 24 | 1.81× | — | ||
| Q2 24 | 1.75× | — | ||
| Q1 24 | 1.13× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-6.3M | $3.8M |
| Free Cash FlowOCF − Capex | — | $-12.7M |
| FCF MarginFCF / Revenue | — | -48.6% |
| Capex IntensityCapex / Revenue | — | 63.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-25.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-6.3M | $3.8M | ||
| Q3 25 | $-2.4M | $8.3M | ||
| Q2 25 | $-942.0K | $-2.9M | ||
| Q1 25 | $-2.8M | $-5.5M | ||
| Q4 24 | $2.2M | $9.0M | ||
| Q3 24 | $-1.2M | $14.5M | ||
| Q2 24 | $-5.2M | $-648.0K | ||
| Q1 24 | $-5.0M | $-7.1M |
| Q4 25 | — | $-12.7M | ||
| Q3 25 | — | $3.0M | ||
| Q2 25 | — | $-5.7M | ||
| Q1 25 | — | $-9.9M | ||
| Q4 24 | — | $-16.2M | ||
| Q3 24 | — | $8.6M | ||
| Q2 24 | — | $-5.1M | ||
| Q1 24 | — | $-15.8M |
| Q4 25 | — | -48.6% | ||
| Q3 25 | — | 11.0% | ||
| Q2 25 | — | -21.5% | ||
| Q1 25 | — | -36.7% | ||
| Q4 24 | — | -57.2% | ||
| Q3 24 | — | 29.1% | ||
| Q2 24 | — | -16.7% | ||
| Q1 24 | — | -50.8% |
| Q4 25 | — | 63.0% | ||
| Q3 25 | — | 19.4% | ||
| Q2 25 | — | 10.7% | ||
| Q1 25 | — | 16.4% | ||
| Q4 24 | — | 88.9% | ||
| Q3 24 | — | 19.6% | ||
| Q2 24 | — | 14.6% | ||
| Q1 24 | — | 28.1% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.46× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DERM
| Qbrexza | $5.5M | 35% |
| Emrosi | $5.0M | 31% |
| Accutane | $3.1M | 19% |
| Other | $2.5M | 15% |
FSP
Segment breakdown not available.
